NCT03929016View on ClinicalTrials.gov

Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

December 6, 2019

Study Completion Date

July 2, 2020

Conditions
Visceral LeishmaniasisCutaneous Leishmaniases
Interventions
DRUG

DNDI-0690

capsules of 10, 100 and 200 mg

DRUG

Placebo of DNDI-0690

capsules of matching placebo

Trial Locations (1)

Unknown

Quotient Sciences, Nottingham

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

lead

Drugs for Neglected Diseases

OTHER

NCT03929016 - Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects | Biotech Hunter | Biotech Hunter